Merck EBITDA 2010-2022 | MRK

Merck annual and quarterly EBITDA history from 2010 to 2022. EBITDA can be defined as earnings before interest, taxes, depreciation and amortization.
  • Merck EBITDA for the quarter ending June 30, 2022 was $6.005B, a 147.73% increase year-over-year.
  • Merck EBITDA for the twelve months ending June 30, 2022 was $23.015B, a 230.39% increase year-over-year.
  • Merck 2021 annual EBITDA was $16.413B, a 81.68% increase from 2020.
  • Merck 2020 annual EBITDA was $9.034B, a 19.6% decline from 2019.
  • Merck 2019 annual EBITDA was $11.236B, a 16.46% decline from 2018.
Merck Annual EBITDA
(Millions of US $)
2021 $16,413
2020 $9,034
2019 $11,236
2018 $13,450
2017 $11,473
2016 $10,970
2015 $13,922
2014 $13,374
2013 $14,653
2012 $16,855
2011 $16,403
2010 $10,736
2009 $6,597
Merck Quarterly EBITDA
(Millions of US $)
2022-06-30 $6,005
2022-03-31 $6,742
2021-12-31 $4,586
2021-09-30 $5,682
2021-06-30 $2,424
2021-03-31 $3,721
2020-12-31 $-2,493
2020-09-30 $3,314
2020-06-30 $3,411
2020-03-31 $4,802
2019-12-31 $-960
2019-09-30 $3,459
2019-06-30 $4,431
2019-03-31 $4,306
2018-12-31 $3,850
2018-09-30 $3,758
2018-06-30 $3,556
2018-03-31 $2,286
2017-12-31 $3,203
2017-09-30 $1,300
2017-06-30 $3,694
2017-03-31 $3,276
2016-12-31 $194
2016-09-30 $4,245
2016-06-30 $3,207
2016-03-31 $3,324
2015-12-31 $3,512
2015-09-30 $3,910
2015-06-30 $3,345
2015-03-31 $3,155
2014-12-31 $3,099
2014-09-30 $3,311
2014-06-30 $3,157
2014-03-31 $3,807
2013-12-31 $3,851
2013-09-30 $4,170
2013-06-30 $3,140
2013-03-31 $3,492
2012-12-31 $3,625
2012-09-30 $4,093
2012-06-30 $4,589
2012-03-31 $4,548
2011-12-31 $3,856
2011-09-30 $4,279
2011-06-30 $4,238
2011-03-31 $4,030
2010-12-31 $1,425
2010-09-30 $3,300
2010-06-30 $3,391
2010-03-31 $2,620
2009-12-31 $1,015
2009-09-30 $2,034
2009-06-30 $1,911
2009-03-31 $1,638
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $217.457B $48.704B
Merck & Co. boasts more than six blockbuster drugs in its portfolio with PD-L1 inhibitor, Keytruda, approved for several types of cancer. Keytruda has played an instrumental role in driving Merck's steady revenue growth in the past few years. Well-known products in Merck's portfolio include Keytruda, Simponi , Januvia and Janumet, Bridion, Isentress, ProQuad, Gardasil, Pneumovax 23, RotaTeq and Belsomra. Merck made its biggest acquisition of Schering-Plough and sold off its Consumer Care business to Bayer. Other key acquisitions include Idenix Pharmaceuticals, Cubist Pharmaceuticals, Rigontec, ArQule and Acceleron Pharma. IMerck spun off products from its Women's Health unit, legacy drugs and biosimilar products into a new publicly traded company called Organon & Co.
Stock Name Country Market Cap PE Ratio
Johnson & Johnson (JNJ) United States $433.657B 16.51
Eli Lilly (LLY) United States $295.599B 37.48
AbbVie (ABBV) United States $250.575B 10.65
Pfizer (PFE) United States $247.449B 7.25
Novo Nordisk (NVO) Denmark $217.019B 28.63
Novartis AG (NVS) Switzerland $165.171B 12.18